亚虹医药(688176) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was CNY 22,874.40, representing a 150% increase compared to the same period last year[4] - The net profit attributable to shareholders was a loss of CNY 62,934,818.04, with a basic and diluted earnings per share of -CNY 0.11[4] - Total operating revenue for Q1 2023 was ¥22,874.40 million, a significant increase from ¥9,149.76 million in Q1 2022, representing a growth of approximately 150%[17] - Net profit for Q1 2023 was -¥62,934.82 million, worsening from -¥47,294.45 million in Q1 2022, reflecting a decline of approximately 33%[18] - Basic and diluted earnings per share for Q1 2023 were both -¥0.11, compared to -¥0.08 in Q1 2022[18] Research and Development - Research and development expenses totaled CNY 56,872,414.28, accounting for 37.86% of the revenue[5] - Research and development expenses for Q1 2023 were ¥56,872.41 million, up from ¥41,253.05 million in Q1 2022, marking an increase of approximately 38%[17] - The increase in net loss was primarily due to an increase in employee numbers and sustained high R&D investment[7] - The company’s core products are still under development, with revenue generated only from specific clinical needs in Hainan Boao Lecheng International Medical Tourism Pilot Zone[5] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,809,688,194.04, a decrease of 2.23% from the end of the previous year[5] - The total current assets decreased to ¥2,689,750,874.13 from ¥2,760,086,589.05, indicating a decline of about 2.6%[14] - The company's total assets as of March 31, 2023, were ¥2,809,688,194.04, down from ¥2,873,779,489.89 at the end of 2022, representing a decrease of approximately 2.2%[14] - The total liabilities decreased to ¥97,010,877.23 from ¥102,979,220.43, showing a reduction of about 5.8%[15] - The company's accounts payable increased to ¥55,293,201.25 from ¥50,225,934.21, reflecting an increase of approximately 10.4%[15] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 30,185[9] - The largest shareholder, PAN KE, holds 22.71% of the shares, totaling 129,465,348 shares[9] Cash Flow - The company reported a net cash flow from operating activities of -CNY 76,863,840.88[4] - Cash flow from operating activities for Q1 2023 was -¥76,863.84 million, compared to -¥69,229.46 million in Q1 2022, indicating a deeper cash outflow[20] - Cash inflow from investment activities in Q1 2023 was ¥1,389.81 million, a substantial increase from ¥196.37 million in Q1 2022[20] - The net cash flow from investing activities was $559,216,797.24, a significant improvement compared to a net outflow of $1,957,022,505.78 in the previous period[21] - Total cash and cash equivalents at the end of the period reached $1,511,726,466.07, up from $1,029,512,600.84 at the beginning of the period[21] Other Financial Metrics - The total equity remained stable at ¥570,000,000.00, unchanged from the previous period[15] - The company reported a foreign exchange gain of ¥8,121.43 million in Q1 2023, compared to ¥6,334.97 million in Q1 2022, indicating an increase of about 28%[18] - The company has not reported any significant new product developments or market expansions during this quarter[12] - The company plans to continue focusing on market expansion and new product development to drive future growth[19] - The impact of exchange rate changes on cash and cash equivalents was $2,800,356.94[21] - The company has not adopted new accounting standards or interpretations that would affect the financial statements for the current year[21]